Veritas Pharma Inc. (CSE: VRT; OTC:
VRTHF;
and Frankfurt: 2VP), (“Veritas” or the “Company”) announces its research arm,
Cannevert Therapeutics Ltd. (“CTL”) filed a provisional patent application to
US Patent and Trademark Office (the “USPTO”) on September 13, 2017 for use of a
specific cannabis strain to enhance the actions of opioid analgesics. An acknowledgement letter from the USPTO was
received recently which provided a filing number of US 62/558,021 for this
application.
VRTHF;
and Frankfurt: 2VP), (“Veritas” or the “Company”) announces its research arm,
Cannevert Therapeutics Ltd. (“CTL”) filed a provisional patent application to
US Patent and Trademark Office (the “USPTO”) on September 13, 2017 for use of a
specific cannabis strain to enhance the actions of opioid analgesics. An acknowledgement letter from the USPTO was
received recently which provided a filing number of US 62/558,021 for this
application.
No comments:
Post a Comment